Latest news with #Neuromodulation
Yahoo
4 days ago
- Business
- Yahoo
Integer Holdings Q2 Earnings Miss Estimates, Revenues Up Y/Y
Integer Holdings Corporation ITGR delivered adjusted earnings per share (EPS) of $1.55 in the second quarter of 2025, which improved 19.2% year over year. However, the figure missed the Zacks Consensus Estimate by 1.3%. The adjustments include expenses related to the amortization of intangible assets and restructuring and restructuring-related charges, among others. GAAP EPS for the quarter was $1.04, up 18.2% from the prior-year quarter. ITGR Revenues in Detail Integer Holdings registered revenues of $476.5 million in the second quarter, up 11.4% year over year. The figure topped the Zacks Consensus Estimate by 2.9%. Organically, revenues increased 10.8%. Robust sales from the majority of the product lines drove the company's top line in the reported period. Integer Holdings Segmental Analysis Integer Holdings operates through three product lines — Cardio and Vascular (C&V); Cardiac Rhythm Management & Neuromodulation (CRM&N) and Other Markets. During the fourth quarter of 2024, management began referring to ITGR's Advanced Surgical, Orthopedics & Portable Medical product line as the Other Markets product line. This was aimed at better capturing the evolving nature of the company's products and ongoing strategic focus. Per management, the name change has no impact on the financial information previously reported. Revenues of the C&V business totaled $286.9 million, up 24% from the prior-year quarter on a reported basis and up 17.6% organically. Strong growth in the segment was driven by organic momentum and recent acquisitions (Precision Coating and VSi Parylene). Electrophysiology remained a key driver, supported by Integer Holdings' broader role in procedures like pulsed field ablation. This compares to our second-quarter projection of $261.9 million. Revenues of the CRM&N business were $171.9 million, up 2.3% year over year on a reported as well as on an organic basis. The solid year-over-year performance was driven by strong growth in emerging Neuromodulation customers with premarket approval products and normalized CRM growth. This compares to our second-quarter projection of $173.8 million for the product line. Integer Holdings' Other Markets revenues amounted to $17.6 million, down 37.9% year over year on a reported basis, and down 1.8% on an organic basis. Per management, this resulted from the execution of the planned multi-year Portable Medical exit announced in 2022. This compares to our second-quarter projection of $26.7 million for Other Markets revenues. Integer Holdings Corporation Price, Consensus and EPS Surprise Integer Holdings Corporation price-consensus-eps-surprise-chart | Integer Holdings Corporation Quote ITGR's Margin Analysis Integer Holdings generated a gross profit of $129.2 million in the second quarter, up 10% year over year. The gross margin in the reported quarter contracted 30 basis points (bps) to 27.1%. We had projected 28.4% of gross margin for the second quarter. Selling, general and administrative expenses were $52.9 million, up 13.9% year over year. Research, development and engineering costs were $14.2 million in the quarter, down 8.8% year over year. Total operating expenses of $69.8 million increased 11% year over year. Adjusted operating profit totaled $81.3 million, reflecting a 14.7% uptick from the prior-year quarter. Adjusted operating margin in the second quarter expanded 50 bps to 17.1%. Integer Holdings' Financial Position Integer Holdings exited the second quarter of 2025 with cash and cash equivalents of $23.1 million compared with $31.7 million at the first-quarter end. Total debt (including the current portion) at the end of second-quarter 2025 was $1.2 billion compared with $1.24 billion at the first-quarter end. Cumulative net cash flow from operating activities at the end of second-quarter 2025 was $75.1 million compared with $70.5 million a year ago. ITGR's 2025 Guidance Integer Holdings has updated its financial outlook for 2025. For 2025, the company now expects revenues between $1,850 million and $1,876 million (implying an improvement of 8-9% from the 2024 reported figure). The Zacks Consensus Estimate is pegged at $1.87 billion. The company now expects full-year adjusted EPS in the band of $6.25-$6.51 (indicating a rise of 18-23% from the 2024 reported figure). The Zacks Consensus Estimate is pegged at $6.33. Our Take Integer Holdings exited the second quarter of 2025 with mixed results. The strong year-over-year top-line and bottom-line performances were impressive. Strength in the majority of the product lines was encouraging. The expansion of the adjusted operating margin bodes well for the stock. Growth was primarily driven by continued momentum in the C&V segment, fueled by new product ramps, especially in electrophysiology and structural heart. The recent acquisitions of Precision Coating and VSi Parylene expanded Integer Holdings' capabilities in differentiated and proprietary coatings, positioning the company for deeper integration into customer roadmaps and future product pipelines. However, modest growth in the CRM&N segment and continued decline in the Other Markets segment remain areas to watch. Integer Holdings' Zacks Rank and Key Picks Integer Holdings currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space that are expected to report earnings soon are Boston Scientific Corporation BSX, Cardinal Health, Inc. CAH and Cencora, Inc. COR. The Zacks Consensus Estimate for Boston Scientific's second-quarter 2025 adjusted earnings per share (EPS) is currently pegged at 72 cents. The consensus estimate for revenues is pegged at $4.89 billion. BSX currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Boston Scientific has an estimated long-term growth rate of 13.2%. BSX's earnings yield of 2.8% compares favorably with the industry's 1.1%. Cardinal Health currently has a Zacks Rank #2. The Zacks Consensus Estimate for fourth-quarter fiscal 2025 adjusted EPS is currently pegged at $2.03, and the same for revenues is pinned at $60.67 billion. Cardinal Health has an estimated long-term growth rate of 10.9%. CAH's earnings yield of 5.7% compares favorably with the industry's 5.5%. Cencora currently carries a Zacks Rank #2. The Zacks Consensus Estimate for third-quarter fiscal 2025 adjusted EPS is currently pegged at $3.78, and the same for revenues is pegged at $80.33 billion. Cencora has an estimated long-term growth rate of 12.8%. COR's earnings yield of 5.4% compares favorably with the industry's 4.1%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Cencora, Inc. (COR) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Citi Upgrades Integer Holdings (ITGR) to Buy, Lifts PT
On May 22, Citi analysts upped Integer Holdings Corporation (NYSE:ITGR)'s stock from 'Neutral' to 'Buy,' increasing the price objective to $140 from $133. The firm noted its healthy Q1 2025 performance, in which sales exceeded expectations. In Q1 2025, the company's sales saw an increase of 7% to $437 million, with organic growth of 6%. Furthermore, segment growth met the expectations, with Cardio & Vascular seeing non-GAAP organic growth of 10.9% YoY. A doctor using a Neuromodulation device to examine a patient's brain activity. After the successful start to the year, Integer Holdings Corporation (NYSE:ITGR)'s management expects YoY sales growth of 8% to 10% in 2025, which Citi analysts believe is conservative. Citi saw that Integer Holdings Corporation (NYSE:ITGR) was largely unaffected by tariffs as it possesses minimal exposure to China and didn't observe huge changes in the customer purchasing behavior. Given the company's positioning in high-growth markets, along with its effective leadership transition, Citi believes that Integer Holdings Corporation (NYSE:ITGR) will accelerate progress moving forward. The YoY growth in Cardio & Vascular sales in Q1 2025 stemmed from new product ramps in electrophysiology and acquisitions. This was partially offset by the impact of fewer shipping days in Q1 2025 as compared to Q1 2024. Integer Holdings Corporation (NYSE:ITGR) operates as a medical device contract development and manufacturing company. While we acknowledge the potential of ITGR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ITGR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None.
The Independent
24-02-2025
- Health
- The Independent
‘Everyone cried': Paralysed woman describes walking after pioneering treatment
A woman who was paralysed as a result of an illness has described how 'everybody cried' when she was able to take her first steps following a pioneering treatment. Claire Trivedi received a type of spinal cord stimulation during a small clinical trial which enabled her to take a few steps using a walker. The 48-year-old from London was paralysed from the waist down in 2017 when a group of abnormal blood vessels in her spinal cord burst. The mother of two is one of 10 spinal cord injury patients who took part in a study assessing new stimulation technology. While taking part in the trial, she was able to restore some functions which were initially thought to be lost after her injury. The technology has been described as a 'hearing aid for the nervous system' and works by stimulating the 'dormant' spine below the patient's injury, combined with 'activity-based therapy'. Experts said the results of the small pilot study were 'game changing'. And Spinal Research chairwoman Tara Stewart said the study suggests 'it's now time to stop talking about spinal cord injury as being incurable'. Ten people aged between 21 and 68 with different levels of spinal cord injuries took part in the study, which has been published in the journal Neuromodulation: Technology At Neural Interface. All participants in the Pathfinder 2 trial, funded by Spinal Research, made significant improvements in their upper body strength, trunk control and balance. And some saw major gains in hand grip and dexterity and lower body functions after using Onward Medical's ARC-EX Therapy combined with rehabilitation. Patients took part in the study for more than a year at Neurokinex rehabilitation facilities in the UK and each had 120 sessions where they were given transcutaneous spinal cord stimulation. The technology delivers electrical pulses through the skin to stimulate the spinal cord which means that signals weakened or interrupted by a spinal cord injury can drive movement. It is coupled with intensive physical therapy, tailored to each patient. Some of those who took part in the trial saw bodily function return a decade after injury or illness. Researchers said that the improvements did not plateau, which suggests further benefits may be achieved with extended treatment. Ms Trivedi said: 'I was told my injury was complete and I just had to get used to my situation, but I refused to give up. 'I dreamed that one day I might take a few steps and my dream came true. 'About 10 weeks before I finished the trial, I took my first steps just using a walking frame, without any leg supports. Everyone cried. 'I was putting my all into the trial and was being rewarded. Even though it was really slow I could see improvements. My legs were getting stronger and I had hope. 'And although all the gains haven't continued, I definitely think the stimulation had a massive impact on my rehab and I can't wait for it to be licensed in the UK.' Ms Stewart added: 'This therapy is not a silver bullet – it works on spared spinal tissue so results will vary widely, and it does need to be paired with proper active rehabilitation over a consistent period of time. 'Even so, this is a game changing moment. It's now time to stop talking about spinal cord injury as being incurable and to stop telling people with this injury that nothing can be done.' Jenny Suggitt, co-investigator of the study, said: 'Participants who have completed the study at this point are seeing changes in their motor function – so their standing ability, walking, core control and sensation changes, as well as changes to their autonomic function – so bladder, bowel and sexual function. 'We are seeing recovery in participants who are over 10 years post injury, and they're regaining function that they never thought possible.' Co-investigator Jane Symonds said: 'Transcutaneous spinal cord stimulation has been described a little bit like a hearing aid for the nervous system, so it's enhancing the signals that the nervous system is receiving. 'And so it's hoped that if somebody, for example, is trying to get some muscle activity in their legs to be able to stand or walk, that when the stimulation is in place, there is a greater level of excitability in the spinal cord, and therefore those nerve impulses are more likely to reach their target destination, and hopefully enable people to use those muscles. 'It has the potential to be a game changer and we're hoping that it's a real breakthrough for people with spinal cord injury.' Dave Marver, chief executive of Onward Medical, said the study 'provides critical insights to the spinal cord injury community, demonstrating that improvements resulting from ARC-EX Therapy extend for at least one year, with no observed plateau'. Harvey Sihota, founder and chief executive of Neurokinex, said: 'There is no doubt that spinal stimulation technology will take spinal cord injury rehab to the next level, bringing even more meaningful functional improvements that offer people greater independence.' Spinal Research is also funding three other UK studies involving use of implantable and external spinal cord stimulation systems. Ms Stewart said: 'With proper investment in the spinal research field we could see significant progress towards a cure for paralysis in the next five to seven years.'
Yahoo
24-02-2025
- Health
- Yahoo
‘Everyone cried': Paralysed woman describes walking after pioneering treatment
A woman who was paralysed as a result of an illness has described how 'everybody cried' when she was able to take her first steps following a pioneering treatment. Claire Trivedi received a type of spinal cord stimulation during a small clinical trial which enabled her to take a few steps using a walker. The 48-year-old from London was paralysed from the waist down in 2017 when a group of abnormal blood vessels in her spinal cord burst. The mother of two is one of 10 spinal cord injury patients who took part in a study assessing new stimulation technology. While taking part in the trial, she was able to restore some functions which were initially thought to be lost after her injury. The technology has been described as a 'hearing aid for the nervous system' and works by stimulating the 'dormant' spine below the patient's injury, combined with 'activity-based therapy'. Experts said the results of the small pilot study were 'game changing'. And Spinal Research chairwoman Tara Stewart said the study suggests 'it's now time to stop talking about spinal cord injury as being incurable'. Ten people aged between 21 and 68 with different levels of spinal cord injuries took part in the study, which has been published in the journal Neuromodulation: Technology At Neural Interface. All participants in the Pathfinder 2 trial, funded by Spinal Research, made significant improvements in their upper body strength, trunk control and balance. And some saw major gains in hand grip and dexterity and lower body functions after using Onward Medical's ARC-EX Therapy combined with rehabilitation. Patients took part in the study for more than a year at Neurokinex rehabilitation facilities in the UK and each had 120 sessions where they were given transcutaneous spinal cord stimulation. The technology delivers electrical pulses through the skin to stimulate the spinal cord which means that signals weakened or interrupted by a spinal cord injury can drive movement. It is coupled with intensive physical therapy, tailored to each patient. Some of those who took part in the trial saw bodily function return a decade after injury or illness. Researchers said that the improvements did not plateau, which suggests further benefits may be achieved with extended treatment. Ms Trivedi said: 'I was told my injury was complete and I just had to get used to my situation, but I refused to give up. 'I dreamed that one day I might take a few steps and my dream came true. 'About 10 weeks before I finished the trial, I took my first steps just using a walking frame, without any leg supports. Everyone cried. 'I was putting my all into the trial and was being rewarded. Even though it was really slow I could see improvements. My legs were getting stronger and I had hope. 'And although all the gains haven't continued, I definitely think the stimulation had a massive impact on my rehab and I can't wait for it to be licensed in the UK.' Ms Stewart added: 'This therapy is not a silver bullet – it works on spared spinal tissue so results will vary widely, and it does need to be paired with proper active rehabilitation over a consistent period of time. 'Even so, this is a game changing moment. It's now time to stop talking about spinal cord injury as being incurable and to stop telling people with this injury that nothing can be done.' Jenny Suggitt, co-investigator of the study, said: 'Participants who have completed the study at this point are seeing changes in their motor function – so their standing ability, walking, core control and sensation changes, as well as changes to their autonomic function – so bladder, bowel and sexual function. 'We are seeing recovery in participants who are over 10 years post injury, and they're regaining function that they never thought possible.' Co-investigator Jane Symonds said: 'Transcutaneous spinal cord stimulation has been described a little bit like a hearing aid for the nervous system, so it's enhancing the signals that the nervous system is receiving. 'And so it's hoped that if somebody, for example, is trying to get some muscle activity in their legs to be able to stand or walk, that when the stimulation is in place, there is a greater level of excitability in the spinal cord, and therefore those nerve impulses are more likely to reach their target destination, and hopefully enable people to use those muscles. 'It has the potential to be a game changer and we're hoping that it's a real breakthrough for people with spinal cord injury.' Dave Marver, chief executive of Onward Medical, said the study 'provides critical insights to the spinal cord injury community, demonstrating that improvements resulting from ARC-EX Therapy extend for at least one year, with no observed plateau'. Harvey Sihota, founder and chief executive of Neurokinex, said: 'There is no doubt that spinal stimulation technology will take spinal cord injury rehab to the next level, bringing even more meaningful functional improvements that offer people greater independence.' Spinal Research is also funding three other UK studies involving use of implantable and external spinal cord stimulation systems. Ms Stewart said: 'With proper investment in the spinal research field we could see significant progress towards a cure for paralysis in the next five to seven years.'
